Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is focused on improving the early detection and management of cancer and other chronic diseases through diagnostics telehealth programs. Its lead product, Aristotle, is a mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. The Care Oncology Clinic offers a supervised treatment regimen for people diagnosed with cancer of any type or stage. AVRT is a physician-led, telehealth program for identifying and managing the early warning signs of cancer and chronic disease. Its program includes a comprehensive online health evaluation; bloodtests to measure markers of inflammation and metabolism; an initial physician consultation; regular physician follow-up appointments and interval screening. Its additional cancer diagnostics include ColonSentry and the Prostate Health Index.


TSX:SZLS - Post by User

Bullboard Posts
Comment by KPOIndustrieson Apr 14, 2020 6:15pm
150 Views
Post# 30909385

RE:The year is 2022

RE:The year is 2022

LOL, this is quite comical, thank you for this. Needed in these times.


Deadornot wrote: StageZero Life Sciences has fully commercialized Aristotle and has already saved over 100,000 lives. The share price is floating at $12.48. James Howard Tripp announces the next set of 10 cancers to be detectable by Aristotle: Phase 2, on June 6th, 2022. It is now June 11th, 2022. KPOindustries: "f*cking Tripp hasn't confirmed anything about Phase 2! All talk no game!" FacBine: "A good read" *Inserts Bashers handbook* Nailbiter: *Creates intelligent post about how Aristotle Phase 1 was successful to bring SZLS from $0.06 to a peak of $14.00, and how Phase 2 will accelerate growth moving forward into 2023* SGordon2: "Nail stop your pump we know all that it will stick at $12.00. Tripp bad CEO. Tripp no do good job. Everyone sell" FacBine: "A good read" *Inserts Bashers handbook*

 

Bullboard Posts